Factbites
 Where results make sense
About us   |   Why use us?   |   Reviews   |   PR   |   Contact us  

Topic: Imatinib


Related Topics
NLN

In the News (Wed 19 Jun 19)

  
  Imatinib - Wikipedia, the free encyclopedia
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes.
Imatinib has passed through Phase III trials for CML, and has been shown to be more effective than the previous standard treatment of α-interferon and cytarabine.
Imatinib was identified in the late 1990s by Dr Brian J. Druker for the pharmaceutical company Novartis as a potential agent for the use in CML.
en.wikipedia.org /wiki/Imatinib   (761 words)

  
 IMATINIB   (Site not responding. Last check: 2007-10-02)
Imatinib is the first anti-cancer drug that doesn't simply kill rapidly-dividing cells, but actually targets the mutated proteins that propel the uncontrolled growth processes.
Imatinib is used in chronic myelogenous leukemia, gastrointestinal stromal tumors and a number of other malignancies.
In laboratory settings, imatinib is being used increasingly as an experimental agent to suppress platelet-derived growth factor by inhibiting its receptor.
www.yotor.org /wiki/en/im/Imatinib.htm   (682 words)

  
 IMATINIB
Imatinib is the first of a new class of antiproliferative drugs, the signal transduction inhibitors.
Imatinib should be taken orally once daily with food and a large glass of water to minimise the risk of gastrointestinal adverse effects.
Imatinib is metabolised by the cytochrome P450 isoenzyme CYP3A4.
www.keele.ac.uk /depts/mm/MTRAC/ProductInfo/summaries/I/IMATINIBs.html   (1284 words)

  
 Imatinib (Gleevec) has activity in AIDS-related Kaposi's sarcoma
Imatinib inhibits important pathways that spur cancer growth, resulting in the regression of KS tumors within 4 weeks in some patients.
Researchers examined the response of Kaposi's sarcoma to imatinib, a drug known to inhibit the PDGF-R and/or c-kit pathways that are responsible for the growth of other cancers, such as chronic myelogenous leukemia, gastrointestinal stromal tumors (GIST), and bone sarcomas of the head and neck.
Researchers reported that the dose of imatinib administered to patients was poorly tolerated and caused severe side effects, including diarrhea, requiring a dose reduction to 200 mg twice daily for all patients by the fourth week of treatment.
www.eurekalert.org /pub_releases/2004-11/asoc-ih112904.php   (658 words)

  
 MedlinePlus Drug Information: Imatinib (Systemic)   (Site not responding. Last check: 2007-10-02)
Imatinib (i-MAT-in-ib) is a new type of medication that prevents and stops the growth of cancer cells.
However, imatinib is not recommended during breast-feeding, because it may cause unwanted effects in nursing babies.
Imatinib may lower your body's resistance and there is a chance you might get the infection the immunization is meant to prevent.
www.nlm.nih.gov /medlineplus/druginfo/uspdi/500297.html   (1551 words)

  
 Gleevec - Drugs & Vitamins - Drug Library - DrugDigest
IMATINIB (Gleevec®) targets specific proteins within distinct cancer cells and stops the cancer cells from growing.
Imatinib is used to treat certain cancers including chronic myelogenous leukemia (CML) and specific sarcomas called GISTs.
Imatinib may increase your risk to bruise or bleed.
www.drugdigest.org /DD/DVH/Uses/0,3915,550246|Gleevec,00.html   (843 words)

  
 Cancer Treatment Information—Chemotherapy, Radiation Oncology, and Surgery
Imatinib works by blocking signals within cancer cells, which prevents a series of chemical reactions that allow the cell to grow and divide.
Imatinib is able to attach to the faulty cell and prevent the "grow and divide" signal, thus stopping the reproduction of cancer cells.
Imatinib should not be given to women who are pregnant, may be pregnant, or are breast-feeding.
www.oncolink.upenn.edu /treatment/article.cfm?c=2&s=10&id=207   (835 words)

  
 ACS :: Cancer Drug Guide: imatinib mesylate
Imatinib mesylate is a protein–tyrosine kinase inhibitor used in molecular targeted therapy to treat patients with chronic myeloid leukemia (CML).
Imatinib mesylate inhibits (blocks) the Bcr–Abl protein tyrosine kinase, which is made by the abnormal Philadelphia chromosome in chronic myeloid leukemia.
Imatinib mesylate also blocks the receptor tyrosine kinase for c–kit, which carries the message for the cancer cells in GIST telling them to divide, causing the cells to stop dividing and to die.
cancer.org /docroot/cdg/content/cdg_imatinib_mesylate.asp?internal=1   (1077 words)

  
 imatinib (oral) - [Medication]
Because imatinib is known to cause birth defects in an unborn baby, women of childbearing age should not become pregnant during treatment.
Imatinib is used to treat the blood cancer chronic myeloid leukemia (CML) and certain types of stomach cancer (stromal GI tumors or GISTs).
Imatinib is in the FDA pregnancy category D. This means that it is known to be harmful to an unborn baby.
www.peacehealth.org /kbase/multum/d04758a1.htm   (1072 words)

  
 Imatinib shows early promise against Ewing’s sarcoma
Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing's sarcoma, a bone tumor in children and adolescents.
Imatinib is a tyrosine kinase inhibitor that has produced high response rates in patients with chronic myelogenous leukemia and gastrointestinal stromal tumors.
Treatment with imatinib also blocked activation of the c-kit receptor tyrosine kinase and resulted in substantial tumor shrinkage in mice bearing human Ewing's sarcoma tumors.
www.eurekalert.org /pub_releases/2002-11/jotn-ise111402.php   (342 words)

  
 News - Imatinib Mesylate May Be Effective in Treating Advanced Gastrointestinal Stromal Tumours
Good response and improvements in performance are seen after imatinib treatment in patients with advanced gastrointestinal stromal tumours, according to observations in 2 patients whose disease was not amenable to surgery, chemotherapy or radiation therapy.
Imatinib mesylate is a selective inhibitor of some protein kinases, including the kit-receptor tyrosine kinase which is expressed in all gastrointestinal stromal tumours.
Imatinib treatment for 1 month improved symptoms, and repeat CT scans indicated a more than 90% improvement in liver metastases.
www.docguide.com /news/content.nsf/news/8525697700573E1885256E1C003B7501   (572 words)

  
 GSI News: Imatinib mesylate in gastrointestinal stromal tumours   (Site not responding. Last check: 2007-10-02)
Imatinib mesylate has also shown antitumour activity in patients with gastrointestinal stromal tumours, almost all of which express c-kit and often CD34, say Drs Savage and Antman.
Imatinib mesylate-mediated inhibition of PDGF receptors may decrease interstitial pressure and thus increase the intratumoural delivery of chemotherapeutic agents, suggest Drs Savage and Antman.
Finally, they note that recent evidence has shown that imatinib mesylate `is active against chronic myeloproliferative disorders associated with a translocation between chromosomes 5 and 12, in which there is a rearrangement and overexpression of the gene for PDGF receptor β'.
www.gistsupport.org /news_20020305_1.asp   (290 words)

  
 Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic ...   (Site not responding. Last check: 2007-10-02)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
High-dose imatinib mesylate (STI571, gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon-alpha (IFN) [abstract].
www.bloodjournal.org /cgi/content/full/101/2/473   (2590 words)

  
 Imatinib Provides Better Leukemia Rx   (Site not responding. Last check: 2007-10-02)
The study shows 87 percent of the patients on imatinib responded to the treatment compared to 35 percent on the combination therapy.
Also, about 97 percent of patients on imatinib did not see their disease advance compared to 91.5 percent of the patients on the combination therapy.
For now, they conclude imatinib is superior to interferon alfa plus low-dose cytarabine as the first-line of therapy in newly diagnosed CML patients.
www.indegene.com /Gyn/Home/indGyn_Ind_News_19-03-2003_1.asp   (277 words)

  
 HighBeam Research: Library Search: Results
Imatinib superior to interferon for newly diagnosed chronic myeloid leukemia.
The patients were randomized to imatinib, 400 mg/d, or the combination of interferon...
Cutaneous reactions to imatinib therapy are increasingly being recognized...
www.highbeam.com /library/search.asp?q=Imatinib&refid=healthcyclopedia   (651 words)

  
 Gleevec Online, Description, Chemistry, Ingredients - Imatinib Mesylate - RxList Monographs
Gleevec® (imatinib mesylate) film-coated tablets contain imatinib mesylate equivalent to 100 mg or 400 mg of imatinib free base.
Imatinib mesylate is designated chemically as 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate and its structural formula is
Imatinib mesylate is a white to off-white to brownish or yellowish tinged crystalline powder.
www.rxlist.com /cgi/generic3/gleevec.htm   (175 words)

  
 Imatinib mesylate
Imatinib is used to treat chronic myelogenous leukemia (CML) and some types of stomach cancer.
Imatinib is the most effective medication, with the fewest side effects, for the treatment of CML.
Imatinib should be administered only under the supervision of a medical oncologist or hematologist.
www.webmd.com /hw/cancer/tv7950.asp   (309 words)

  
 Induction of imatinib metabolism by hypericum perforatum -- Smith et al. 104 (4): 1229 -- Blood   (Site not responding. Last check: 2007-10-02)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
www.bloodjournal.org /cgi/content/full/104/4/1229   (695 words)

  
 Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs
M imatinib (the concentration used to select the resistant sublines) to establish the baseline profile of their response (Figure 1).
The response of progenitor cells from CML patients in blast crisis relapsing on imatinib therapy was investigated by CFU-GM assays in the presence or absence of imatinib, Ara-C, DNR, HU or HHT (Figure 5).
Overall, combinations of the individual chemotherapeutic drugs with imatinib were near-additive or synergistic at high effect levels, and the degree of synergy was greater in the imatinib-resistant than in the sensitive lines (Table 2).
www.nature.com /leu/journal/v16/n12/full/2402775a.html   (6163 words)

  
 Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to ...   (Site not responding. Last check: 2007-10-02)
Imatinib Mesylate May Improve Fasting Blood Glucose in Diabetic Ph+ Chronic Myelogenous Leukemia Patients Responsive to Treatment -- Breccia et al.
Patient 3 was treated with imatinib as first-line therapy.
Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
www.jco.org /cgi/content/full/22/22/4653   (1013 words)

  
 Final Appraisal Determination: Imatinib for chronic myeloid leukaemia
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on imatinib for chronic myeloid leukaemia and submitted it to the Institute.
Protocol: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
Assessment Report: The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase
www.nice.org.uk /page.aspx?mode=text&o=84382   (192 words)

  
 Opportunities and challenges in the development of kinase inhibitor therapy for cancer -- Sawyers 17 (24): 2998 -- ...   (Site not responding. Last check: 2007-10-02)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor.
www.genesdev.org /cgi/content/full/17/24/2998   (8705 words)

  
 Erythropoietin Overcomes Imatinib-Induced Apoptosis and Induces Erythroid Differentiation in TF-1/bcr-abl Cells -- ...   (Site not responding. Last check: 2007-10-02)
TF-1/bcr-abl cells were cultured with imatinib (1 µM) in the presence or absence of GM-CSF (1 ng/mL) or EPO (1 U/mL).
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
stemcells.alphamedpress.org /cgi/content/full/22/4/609   (3456 words)

  
 Gleevec Indications, Dosage, Storage, Stability - Imatinib Mesylate - RxList Monographs
Gleevec® (imatinib mesylate) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase.
Gleevec is also indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
The recommended dosage of Gleevec® (imatinib mesylate) is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis.
www.rxlist.com /cgi/generic3/gleevec_ids.htm   (951 words)

  
 Elimination of Imatinib Mesylate and Its Metabolite N-Desmethyl-Imatinib -- Bornhäuser et al. 23 (16): 3855 -- ...   (Site not responding. Last check: 2007-10-02)
concentration of imatinib and its metabolite was 5.18 (18%).
Peng B, Hayes M, Resta D, et al: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
O'Brien SG, Meinhardt P, Bond E, et al: Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
www.jco.org /cgi/content/full/23/16/3855   (752 words)

Try your search on: Qwika (all wikis)

Factbites
  About us   |   Why use us?   |   Reviews   |   Press   |   Contact us  
Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.